Why some treatments shave muscle too
Researchers warn that the fat loss from GLP‑1 drugs and from bariatric surgery often comes with a modest loss of muscle, which matters for strength and long‑term health. (A recent summary highlights that both interventions significantly reduce fat but also cause modest muscle loss, and clinical trials show about 10–15% of people on GLP‑1s are “non‑responders” who don’t lose at least 5% of body weight.) (sciencedaily.com) (bostonglobe.com)
Glucagon-like peptide 1 drugs work by making food leave the stomach more slowly and by turning down appetite signals in the brain, so people usually eat less without white-knuckling every meal. A 2026 New England Journal of Medicine review says that same weight loss can also come with loss of muscle and bone mass, not just fat. (nejm.org) Body weight is really two big buckets: fat mass, which stores energy, and fat-free mass, which includes muscle, organs, bone, and water. The new Vanderbilt analysis looked past the bathroom scale and asked how those buckets changed after treatment. (jamanetwork.com) The Vanderbilt team studied 3,066 adults in routine care, including 1,257 people who had bariatric surgery from 2017 to 2022 and 1,809 people treated with semaglutide or tirzepatide from 2018 to 2023. They tracked body composition for up to 24 months using bioelectrical impedance, a clinic test that estimates body compartments from a tiny electrical current. (sciencedaily.com, jamanetwork.com) What they found was not “fat only” loss. Both bariatric surgery and the drugs were linked to large drops in fat mass, modest drops in fat-free mass, and a higher fat-free-mass-to-fat-mass ratio over 24 months. (jamanetwork.com) That pattern matches older drug trials. In the 2021 STEP 1 trial, semaglutide cut body weight by 14.9% at 68 weeks, and 86.4% of participants lost at least 5% of body weight, but body-composition scans showed lean mass fell along with fat mass. (nejm.org, nejm.org) The same thing showed up with tirzepatide. In the 2022 SURMOUNT-1 trial, people on tirzepatide lost 15.0% to 20.9% of body weight by week 72, and the trial reported that fat mass fell by about three times as much as lean mass, which improved body composition overall but still meant some lean tissue was lost. (nejm.org) Doctors worry about that because muscle is not decorative tissue. Muscle helps people climb stairs, recover from illness, avoid falls as they age, and keep resting energy use higher than it would be with less lean mass. (nature.com, nature.com) The risk is not the same for everyone. A Nature paper published on April 8, 2026 analyzed 27,885 people using these drugs and found substantial person-to-person variation in both weight-loss benefit and side effects, with part of that variation tied to genes near the drug targets. (nature.com) That helps explain why some patients barely lose weight at all. The recent reporting around these drugs says roughly 10% to 15% of users do not lose at least 5% of body weight in clinical trials, which means a person can end up paying for months of treatment, dealing with nausea, and still not getting a big change on the scale. (bostonglobe.com, nature.com) Researchers are already trying to solve the muscle problem directly. One phase 2 trial called EMBRAZE is testing apitegromab alongside tirzepatide to see whether blocking myostatin, a protein that restrains muscle growth, can preserve lean mass during drug-driven weight loss. (clinicaltrials.gov, nature.com) For now, the picture is less “these treatments melt fat” than “these treatments remodel the body.” The fat loss is real, the health benefits can be real, and the next fight in obesity medicine is making sure strength does not shrink at the same time. (sciencedaily.com, nejm.org, nature.com)
